On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s disease. The findings demonstrated significant clinical remission and ...
TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
Johnson & Johnson JNJ announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine ...
Zacks Investment Research on MSN
JNJ's Tremfya gets EU approval for pediatric plaque psoriasis
Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...
"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...
Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the ...
NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible for treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback